The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 1 study of VX15/2503, a humanized IgG4 anti-SEMA4D antibody, in advanced cancer patients (pts).
Amita Patnaik
Consultant or Advisory Role - Vaccinex
Research Funding - Vaccinex
Ramesh K. Ramanathan
Consultant or Advisory Role - Vaccinex
Honoraria - Vaccinex
Research Funding - Vaccinex
Drew Warren Rasco
Research Funding - Vaccinex
Glen J. Weiss
Honoraria - Celgene; Genentech; Medscape; Pfizer; Quintiles
Valerie Campello-Iddison
Employment or Leadership Position - Vaccinex
Stock Ownership - Vaccinex
Cynthia Eddington
Employment or Leadership Position - Vaccinex
Stock Ownership - Vaccinex
Terrence L. Fisher
Employment or Leadership Position - Vaccinex
Stock Ownership - Vaccinex
Danielle Mutz
No relevant relationships to disclose
Lisa Blaydorn
No relevant relationships to disclose
Anthony W. Tolcher
Consultant or Advisory Role - A.P. Pharma (U); Abbott Laboratories (U); AbGenomics International (U); Abraxis BioScience (U); Actavis (U); Adnexus (U); Ambit BioSciences (U); Amgen (U); Aragon Pharmaceuticals (U); ARIAD (U); Arresto (U); Astellas Pharma (U); Astex Therapeutics (U); Bayer (U); BIND Biosciences (U); Bristol-Myers Squibb Japan (U); Celator Pharmaceuticals (U); Celgene (U); Clovis (U); Complete Genomics (U); Cougar Biotechnology (U); Curis (U); CytomX Therapeutics (U); Daiichi Sankyo (U); De Novo Pharmaceuticals (U); Dendreon (U); Dicerna (U); Eisai (U); EMD Serono (U); Endo Pharmaceuticals (U); Enzon (U); Everist Genomics (U); Exelixis (U); Five Prime Therapeutics (U); Galapagos NV (U); Genentech (U); Geron (U); GlaxoSmithKline (U); HUYA Bioscience International (U); Icon Clinical Research (U); Inovio Pharmaceuticals (U); Insert Therapeutics (U); Intellikine (U); Invivis (U); Janssen (U); Johnson & Johnson (U); Lilly (U); Merck (U); MethylGene (U); Micromet (U); NantWorks (U); Nektar (U); Neurmedicines (U); Novartis (U); Oncogenex (U); OncoMed (U); Onyx (U); Otsuka (U); Pfizer (U); Pharmacyclics (U); PPD Inc. (U); Precision Health Holdings (U); ProNAi (U); Regeneron (U); Sanofi (U); Spectrum Pharmaceuticals (U); Sunovion (U); Triphase Accelerator Corp (U); Vaccinex (U); Veeda Oncology (U); Zyngenia (U)
Honoraria - The START Center for Cancer Care
John E. Leonard
Employment or Leadership Position - Vaccinex
Stock Ownership - Vaccinex